Jesùs Marìa H. R.
- Country
- Spain
- Department
- Hematology
Research Overview
- Blinatumomab and Combination Therapy Versus Standard of Care in Older Adults With Newly Diagnosed Philadelphia-Negative B-Cell Precursor Acute Lymphoblastic Leukemia
- Phase 1/2 Study of Subcutaneous Blinatumomab in Adults and Adolescents with Relapsed/Refractory or MRD+ B-cell Precursor Acute Lymphoblastic Leukemia
- Phase 3 Randomized Double‑Blind Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo + Ruxolitinib in JAK‑Inhibitor‑Naive Adults with Myelofibrosis
Data & Insights
Has run more than one trial at 185 of 333 partner sites.
Specializations
Myelofibrosis Treatment
The investigator specializes in treating various forms of myelofibrosis, including primary myelofibrosis, post-polycythemia vera myelofibrosis, and post-essential thrombocythemia myelofibrosis. Their research encompasses both treatment-naïve patients and those unresponsive to conventional therapies.
- JAK inhibitor therapies
- Novel therapeutic combinations
- Spleen volume reduction treatments
Particular attention is given to managing anemia in myelofibrosis patients and exploring innovative treatment approaches for those with moderate thrombocytopenia.
Hematologic Conditions
The investigator focuses on treating complex blood disorders, particularly essential thrombocythemia and hypereosinophilic syndrome. Their work includes evaluating novel therapeutic approaches for patients who have shown inadequate response to standard treatments.
- Essential thrombocythemia management
- Hypereosinophilic syndrome treatments
- Advanced myeloid neoplasms
Special emphasis is placed on developing treatment strategies for patients who are intolerant to conventional therapies.
Leukemia Research
The investigator studies treatment approaches for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, with a focus on newly diagnosed cases. Their research explores combination therapies involving targeted agents and reduced-intensity chemotherapy.
- First-line therapy optimization
- Targeted treatment approaches
- Combination therapy protocols
The work includes evaluation of minimal residual disease and complete response rates in leukemia patients.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.